三种喹诺酮类药物的体外抗菌活性和防突变能力评价

罗开萍 ,  徐杰 ,  张险峰 ,  石新 ,  杭永付

中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (8) : 1064 -1069.

PDF (452KB)
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (8) : 1064 -1069. DOI: 10.12092/j.issn.1009-2501.2026.08.006
基础研究

三种喹诺酮类药物的体外抗菌活性和防突变能力评价

作者信息 +

Evaluation of the in vitro antibacterial activity and mutant prevention potential of three quinolone antibiotics

Author information +
文章历史 +
PDF (461K)

摘要

目的: 探讨奈诺沙星、左氧氟沙星及莫西沙星三种喹诺酮类抗菌药物对革兰氏阳性菌(G+)和革兰氏阴性菌(G−)的体外抑菌效果,为临床合理使用提供依据。方法: 采用微量肉汤稀释法(broth microdilution method)对 292 株临床分离菌株[包括甲氧西林敏感金黄色葡萄球菌(methicillin-susceptible Staphylococcus aureus,MSSA)、表皮葡萄球菌、屎肠球菌、纹带棒状杆菌、大肠埃希菌、肺炎克雷伯菌、铜绿假单胞菌和鲍曼不动杆菌]进行药物敏感性试验,比较三种药物的最低抑菌浓度(MIC)分布、药效学特征。用琼脂稀释法进一步测定部分菌株的防突变浓度(MPC),评估防突变能力。结果: 在 G+菌中,奈诺沙星对金黄色葡萄球菌(MIC90=16 μg/mL)、表皮葡萄球菌(MIC90=2 μg/mL)及纹带棒状杆菌(MIC90=4 μg/mL)的活性均优于左氧氟沙星和莫西沙星。在耐甲氧西林金黄色葡萄球菌(methicillin-resistant Staphylococcus aureus,MRSA)菌株中,奈诺沙星的敏感率达 66.96%。在 G−菌中,铜绿假单胞菌对左氧氟沙星的 MIC90 为 2 μg/mL,低于奈诺沙星和莫西沙星(均为 4 μg/mL);肺炎克雷伯菌、大肠埃希菌及鲍曼不动杆菌对三药的 MIC90 多为 64 μg/mL,整体敏感性较低。在防突变能力方面,MSSA 中奈诺沙星的 MPC90 为 2 μg/mL,低于莫西沙星(4 μg/mL)和左氧氟沙星(16 μg/mL),其选择指数(selection index,SI)的范围最小;在耐药 G−菌中三药 MPC90 普遍较高,SI 也明显增大。但左氧氟沙星对耐药铜绿假单胞菌的 MPC90(16 μg/mL)低于莫西沙星(32 μg/mL)和奈诺沙星(64 μg/mL)。结论: 奈诺沙星在金黄色葡萄球菌(含 MRSA)等 G+菌中显示出更强的抗菌活性,且在 MSSA 中表现出最强的防突变能力。左氧氟沙星在铜绿假单胞菌中维持了较好的抗菌活性,且其防突变浓度在受试药中相对较低。临床应用中应结合病原体类型和耐药风险进行选择。

Abstract

AIM: To evaluate the in vitro antibacterial efficacy of three quinolones-nemonoxacin, levofloxacin, and moxifloxacin-against Gram-positive (G+) and Gram-negative (G−) bacteria, providing a scientific basis for rational clinical use. METHODS: Drug susceptibility tests were conducted on 292 clinical isolates (including Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecium, Corynebacterium striatum, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii) using the broth microdilution method to compare the distribution of minimum inhibitory concentrations (MICs) and pharmacodynamic characteristics. The mutant prevention concentration (MPC) of selected strains was further determined by the agar dilution method to evaluate their mutant prevention capabilities. RESULTS: For G+ bacteria, nemonoxacin exhibited superior activity against Staphylococcus aureus (MIC90=16 μg/mL), Staphylococcus epidermidis (MIC90=2 μg/mL), and Corynebacterium striatum (MIC90=4 μg/mL) compared to levofloxacin and moxifloxacin. In MRSA strains, the susceptibility rate of nemonoxacin reached 66.96%. For G− bacteria, the MIC90 of levofloxacin against P. aeruginosa was 2 μg/mL, which was lower than that of nemonoxacin and moxifloxacin (both 4 μg/mL). For K. pneumoniae, E. coli, and A. baumannii, the MIC90 values for all three drugs were mostly 64 μg/mL, indicating overall low susceptibility. In terms of mutant prevention, nemonoxacin showed an MPC90 of 2 μg/mL in MSSA, which was lower than that of moxifloxacin (4 μg/mL) and levofloxacin (16 μg/mL), with the narrowest range of selection index (SI). In resistant G− bacteria, the MPC90 and SI values for all three drugs were generally higher. However, the MPC90 of levofloxacin against resistant P. aeruginosa (16 μg/mL) was lower than that of moxifloxacin (32 μg/mL) and nemonoxacin (64 μg/mL). CONCLUSION: Nemonoxacin demonstrates stronger antibacterial activity against G+ bacteria such as S. aureus (including MRSA) and possesses the most potent mutant prevention capability in MSSA. Levofloxacin maintains favorable antibacterial activity against P. aeruginosa, and its MPC is relatively lower among the tested drugs. Clinical selection should be based on the specific pathogen type and the risk of resistance.

关键词

奈诺沙星 / 左氧氟沙星 / 莫西沙星 / 最低抑菌浓度 / 防突变浓度

Key words

nemonoxacin / levofloxacin / moxifloxacin / minimum inhibitory concentration / mutant prevention concentration

引用本文

引用格式 ▾
罗开萍,徐杰,张险峰,石新,杭永付. 三种喹诺酮类药物的体外抗菌活性和防突变能力评价[J]. 中国临床药理学与治疗学, 2026, 31(8): 1064-1069 DOI:10.12092/j.issn.1009-2501.2026.08.006

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

Tang K, Zhao H.Quinolone antibiotics: resistance and therapy[J].Infect Drug Resist, 2023, 16: 811-820.

[2]

She P, Luo Z, Chen L, et al. Efficacy of levofloxacin against biofilms of Pseudomonas aeruginosa isolated from patients with respiratory tract infections in vitro[J].Microbiologyopen, 2019, 8(5): e00720.

[3]

Sionidou M, Manika K, Pitsiou G, et al. Moxifloxacin in chronic obstructive pulmonary disease: pharmacokinetics and penetration into bronchial secretions in ward and intensive care unit patients[J].Antimicrob Agents Chemother, 2019, 63(3): e01974-18.

[4]

郝敏, 秦晓华. 无氟喹诺酮类抗菌新药-奈诺沙星[J].中国感染与化疗杂志, 2018, 18(6): 663-671.

[5]

Chen PY, Ho MW, Lu PL, et al. Comparative in vitro antibacterial activity of nemonoxacin and other fluoroquinolones in correlation with resistant mechanisms in contemporary thicillin-resistant Staphylococcus aureus blood isolates in Taiwan[J].Ann Clin Microbiol Antimicrob, 2025, 24(1): 5.

[6]

Li Y, Zhu D, Sun S, et al. A multicentre, randomised, double-blind, double-dummy, parallel-controlled, phase 3 clinical trial assessing the efficacy and safety of intravenous nemonoxacin malate vs. levofloxacin for community-acquired pneumonia in adult patients[J].Int J Antimicrob Agents, 2024, 64(2): 107235.

[7]

Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard-11th edition[S].CLSI document M07-Ed11. Wayne, PA: CLSI; 2018.

[8]

Kawamura M, Fujimura S, Tokuda K, et al. Mutant selection window of disinfectants for Staphylococcus aureus and Pseudomonas aeruginosa[J].J Glob Antimicrob Resist, 2019, 17: 316-320.

[9]

Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; 34th Informational Supplement. CLSI document M100-Ed34[S]. Wayne, PA: CLSI;2024.

[10]

Grillon A, Schramm F, Kleinberg M, et al. Comparative activity of ciprofloxacin, levofloxacin and moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia assessed by minimum inhibitory concentrations and time-kill studies[J].PLoS One, 2016, 11(6): e0156690.

[11]

Ibrahim NH, Somily AM, Bassyouni RH, et al. Comparative study assessing the effect of tigecycline and moxifloxacin in prevention of Acinetobacter baumannii biofilm[J].Life Sci, 2012, 9(3): 1016-1024.

[12]

Jean SS, Chang LW, Hsueh PR.Tentative clinical breakpoints and epidemiological cut-off values of nemonoxacin for Streptococcus pneumoniae and Staphylococcus aureus isolates associated with community-acquired pneumonia[J].J Glob Antimicrob Resist, 2020, 23: 388-393.

[13]

Qin X, Huang H.Review of nemonoxacin with special focus on clinical development[J].Drug Des Devel Ther, 2014, 8: 765-774.

[14]

Chen YH, Liu CY, Lu JJ, et al. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan[J].J Antimicrob Chemother, 2009, 64(6): 1226-1229.

[15]

张菁, 吕媛, 于凯江, 等. 抗菌药物药代动力学/药效学理论临床应用专家共识[J].中华结核和呼吸杂志, 2018, 41(6): 409-446.

[16]

Yang JJ, Cheng A, Tai HM, et al. Selected mutations by nemonoxacin and fluoroquinolone exposure among relevant Gram-positive bacterial strains in Taiwan[J].Microb Drug Resist, 2020, 26(2): 110-117.

[17]

Hooper DC, Jacoby GA.Mechanisms of drug resistance: quinolone resistance[J].Ann NY Acad Sci, 2015, 1354(1): 12-31.

[18]

曾静, 魏海燕, 马丹, 等. 革兰氏阴性菌耐药机制初探[J].中国口岸科学技术, 2022, 4(S2): 4-10.

基金资助

江苏省医学重点学科(ZDXK202247)

白求恩公益基金会-社区感染性疾病科研能力建设项目(BCF-XC-SQ-20221206-10)

AI Summary AI Mindmap
PDF (452KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉